Eli Lilly and Company (LLY) Institutional Ownership & Insider Trading

4,607 institutions reported holding Eli Lilly and Company shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 364 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

LLYEli Lilly and CompanyFollow LLY — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 1.20T
P/E TTM: 42.7
Dividend yield: 0.5%
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

4,607 institutions held 83.7% of the shares. Across filers that reported both quarters, shares held changed -0.0%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	4,607	788	-0.0%	1819	313	1134	75
Mar 26	4,313	776	-0.7%	1547	134	1353	185
Dec 25	4,303	786	-0.1%	1352	315	1276	73
Sep 25	3,819	773	+0.1%	1456	131	1165	127
Jun 25	3,825	781	-6.6%	1447	140	1127	137
Mar 25	3,820	819	+7.0%	1414	167	1151	123
Dec 24	3,761	778	-2.2%	1218	128	1176	167
Sep 24	3,549	764	-2.5%	1230	149	1063	92

Eli Lilly and Company — questions

Who owns Eli Lilly and Company stock?: 4,607 institutions reported Eli Lilly and Company shares in 13F filings for the quarter ended 2026-06-30. The largest: LILLY ENDOWMENT INC (9.6%), BlackRock, Inc. (7.2%), VANGUARD CAPITAL MANAGEMENT LLC (5.7%).
Are Eli Lilly and Company insiders buying or selling?: 364 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Eli Lilly and Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.